References
- Tarantola RM, Folk JC, Boldt HC, et al. Intravitreal bevacizumab during pregnancy. Retina. 2010;30(9):1405–1411.
- Kianersi F, Ghanbari H, Naderi Beni Z, et al. Intravitreal vascular endothelial growth factor (VEGF) inhibitor injection in unrecognised early pregnancy. Invest New Drugs. 2016;34(5):650–653.
- Briggs Gerald G, Freeman Roger K, Yaffe Sumner J. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health; 2015.
- Wang X, Chen C, Wang L, et al. Conception,early pregnancy loss, and time to clinical pregnancy: a populationbasedprospective study. FertilSteril. 2003;79(3):577–584.
- Polizzi S, Ferrara G, Restaino S, et al. Inadvertent use of bevacizumab in pregnant women with diabetes mellitus type 1. J Basic Clin Physiol Pharmacol. 2015;26(2):161–163.
- Sarmad A, Lip PL. Intravitreal anti-vascular endothelial growth factor in early pregnancy and the complex management of advance diabetic retinopathy and maculopathy during pregnancy. Acta Ophthalmol. 2016;94(8):e812–e813.
- Petrou P, Georgalas I, Giavaras G, et al. Early loss of pregnancy after intravitreal bevacizumab injection. Acta Ophthalmol. 2010;88(4):e136.
- GóMez Ledesma I, de Santiago Rodrı´Guez MÁ, FollanaNeira I, et al. Neovascular membrane and pregnancy. Treatment with bevacizumab. Arch Soc. Esp.Oftalmol. 2013;88:453–454.
- Knudsen UB, Hansen V, Juul S, et al. Prognosis of a new pregnancy following previous spontaneous abortions. Eur J Obstet Gynecol Reprod Biol. 1991;39(1):31–36.